InnoCare Appoints Dr. Sean Zhang as Chief Medical Officer

On February 28, 2021 InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, reported that the Company appointed Dr. Sean Zhang as Chief Medical Officer (CMO) (Press release, InnoCare Pharma, FEB 28, 2021, View Source [SID1234575798]). Reporting to the Co-founder, Chairwoman and CEO, Dr. Jasmine Cui. Dr. Zhang will be responsible for global clinical development strategy and execution for InnoCare. Dr. Zhang is based in U.S., thus demonstrating InnoCare’s ongoing commitment to globalization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a physician scientist, Dr. Zhang has more than 30 years working experience in clinical practice, academic research and drug discovery and development. Before joining InnoCare, Dr. Zhang served as CMO and Member of the Board of Directors of Hengrui Therapeutics Inc. (HTI) before his promotion to CEO. HTI is a joint venture between Jiangsu Hengrui Medicine and a leading global investment firm focused on oncology, autoimmune and other unmet medical-need disease areas. Under Dr. Zhang’s leadership, his team has successfully launched two global phase III oncology studies in US and EU and one global phase II study for autoimmune disease, submitted more than ten U.S. FDA Investigational New Drug applications (INDs) and conducted a number of successful FDA meetings on several major development programs. Before HTI, Dr. Zhang assumed increasing responsibilities in clinical development at GlaxoSmithKline, Bristol-Myers Squibb, and Johnson and Johnson. He also worked as staff gastroenterologist and clinical investigator at 301 Hospital in Beijing in his early career.

"It is my pleasure to welcome Dr. Zhang to join InnoCare," said Dr. Cui. "We established this senior role in U.S. to not only expand our global footprint but also to enhance our clinical development competency globally. Dr. Zhang has accumulated solid experience in clinical development, drug discovery and business leadership, and he has established a broad network with physicians in both the U.S. and China. I believe his on-boarding will further advance our ongoing clinical trials in the field of oncology and autoimmune diseases worldwide."

"It is my honor and privilege to join InnoCare at this exciting moment in the company’s evolution," said Dr. Zhang. "I am very impressed with InnoCare’s strong innovation capabilities and rich product pipelines. I look forward to working closely with our clinical team and partners to further advance our clinical development pipelines to benefit patients worldwide."

Dr. Zhang completed his postdoctoral training at Sepulveda VA Hospital of UCLA School of Medicine in Los Angeles and Michigan State University. After passing the United States Medical License Examination (USMLE), Dr. Zhang completed his medical followship training at Clinical Center of U.S. National Institute of Health in 2006. He was elected Fellow of American College of Clinical Pharmacology (FCP) in 2012. He is also board of director of Sino-American Pharmaceutical Association (SAPA).